BofA analyst Joshua Shanker raised the firm’s price target on WTW (WTW) to $360 from $336 and keeps a Neutral rating on the shares. The firm noted that, at its 2024 investor day, the company highlighted Health, Wealth and Career as having an overall mid-single-digit growth profile, with the firm projected 2025 and 2026 organic growth of 5% for this segment, in line with the comments. The relatively limited potential upside compared to the firm’s price target underlies its Neutral thesis, the analyst tells investors in a research note, adding that the firm believes current valuation adequately encompasses turnaround progress compared with historical operational challenges and risks related to closing the TRANZACT deal.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on WTW:
- WTW price target raised to $380 from $365 at Truist
- WTW price target raised to $357 from $336 at Evercore ISI
- WTW price target raised to $380 from $340 at Wells Fargo
- WTW price target raised to $378 from $359 at Keefe Bruyette
- WTW outlines growth, value creation strategy at 2024 Investor Day
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
